Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zirconium Zr 89-DFO-vandortuzumab vedotin

A radioimmunoconjugate composed of the radioisotope zirconium Zr 89 conjugated to an antibody that targets six transmembrane epithelial antigen of the prostate 1 (STEAP1) that can potentially be used as a prostate cancer tracer during positron emission tomography (PET). Upon administration of zirconium Zr 89-DFO-vandortuzumab vedotin, the antibody moiety DFO-vandortuzumab vedotin binds to STEAP1 on prostate cancer cells. In turn, Zr 89 allows for the visualization of those cells using PET. STEAP1, a six-transmembrane domain protein, is overexpressed on the surface of prostate cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:89Zr-DFO-MSTP2109A
89Zr-DFO-vandortuzumab vedotin
zirconium Zr 89 DFO-MSTP2109A
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search